Intra-Cellular Therapeutics

FDA Building 2
Biotech

FDA calls off AdComm for Intra-Cellular's schizophrenia prospect

Intra-Cellular Therapies’ lead asset hit a snag Tuesday afternoon as the FDA canceled an advisory panel meeting scheduled for next Wednesday.
Amirah Al Idrus Jul 24, 2019 7:25am
Dollar bills falling

Intra-Cellular raises $150M as it preps schizophrenia drug filing

Oct 3, 2017 7:35am
Closeup of stock prices

Intra-Cellular tanks on PhIII schizophrenia failure

Sep 29, 2016 1:13pm